All posts by medical

Sitting on a Pile of Cash? Here is Another Coronavirus Immunology Play, Take a Shot – Live Trading News

$INO

Today. Inovio Pharmaceuticals Inc. (NASDAQ:INO) was reiterated as Buy and its price target was raised to 17 from 13 at HC Wainwright after announcing promising MERS data that could set the stage for a potential COVID-19 vaccine. My work augurs for a run to 29/30+ if it happens.

This is a speculation, if you can manage the risk, take a shot, and if the stock 2Xs be prudent, sell half of the position and ride it for free.

Wednesday, INO finished at 13.74, -0.01, Vs its 52 wk high at 19.36 on higher than average volume. Key Support is at 8.45 and the Resistance is Nil. 3 of our Key technical indicators have turned Very Bullish, 1 long term.

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.

Its SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens.

The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).

Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agencys Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. Inovio Pharmaceuticals, Inc. was founded in Y 1979 and is HQd in Plymouth Meeting, Pennsylvania.

Have a healthy day, Keep the Faith!

immunology, INO, resistance, risk, stock, support, vaccine

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of The Red Roadmasters Technical Report on the US Major Market Indices, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Continued here:
Sitting on a Pile of Cash? Here is Another Coronavirus Immunology Play, Take a Shot - Live Trading News

Outlook on the Worldwide Research Antibodies Industry to 2024 – Mergers, Acquisitions, Agreements and Collaborations – GlobeNewswire

Dublin, May 01, 2020 (GLOBE NEWSWIRE) -- The "Research Antibodies Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.

The research antibodies market is estimated to be valued at US$1.032 billion in 2018 and is projected to grow further in the coming years. Research antibodies react to the presence of specific antibody make them indispensable tool for the clinical as well as basic researches. Due to the high specificity and selectivity of the antibodies, they are being used in wide variety of applications such as biochemical tools for a range of applications including selection, identification, purification and as therapeutics.

Routine procedures such as western blot, flow cytometry, immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA) and many others also rely on these antibodies. Rising investments for the research and development of the research antibodies coupled with the growing industry-Academia collaboration will drive the market during the given forecast period. Rising demand for the personalized medicine and protein therapeutics will also boost the market growth. However, rising quality concerns regarding these antibodies and large amount of time and cost might restrain the market of research antibodies during the given time frame.

This report is an exhaustive study that aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by type, research area, technology, and geography.

The research antibodies market has been segmented based on type, research area, technology, and geography. By type, the market has been segmented on the basis of monoclonal antibodies (mAbs), and polyclonal antibodies (pAbs). By research area, the market has been segmented into oncology, infectious diseases, immunology, neurology, and others. By technology, the market has been divided into western blotting, flow cytometry, enzyme-linked immunosorbent assay (ELISA), and others.

Regional analysis has been provided with detailed analysis and forecast for the period 2018 to 2024. The global market has been broken down into North America, South America, Europe, Middle East and Africa (MEA), and the Asia Pacific regions. The report also analyzes 15 countries across these regions with thorough analysis and forecast along with prevailing market trends and opportunities which each of these countries present for the manufacturers.

Major players in the research antibodies market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the research antibodies market.

Key Topics Covered:

1. Introduction1.1. Market Definition1.2. Market Segmentation

2. Research Methodology2.1. Research Data2.2. Assumptions

3. Executive Summary3.1. Research Highlights

4. Market Dynamics4.1. Market Drivers4.2. Market Restraints4.3. Porters Five Forces Analysis4.3.1. Bargaining Power of Suppliers4.3.2. Bargaining Power of Buyers4.3.3. Threat of New Entrants4.3.4. Threat of Substitutes4.3.5. Competitive Rivalry in the Industry4.4. Industry Value Chain Analysis

5. Research Antibodies Market Analysis, By Type5.1. Introduction5.2. Monoclonal Antibodies (mAbs)5.3. Polyclonal Antibodies (pAbs)

6. Research Antibodies Market Analysis, By Research Area6.1. Introduction6.2. Oncology6.3. Infectious Diseases6.4. Immunology6.5. Neurology6.6. Others

7. Research Antibodies Market Analysis, By Technology7.1. Introduction7.2. Western Blotting7.3. Flow Cytometry7.4. Enzyme-Linked Immunosorbent Assay (ELISA)7.5. Others

8. Research Antibodies Market Analysis, By Geography8.1. Introduction8.2. North America8.2.1. North America Research Antibodies Market, By Type, 2018 to 20248.2.2. North America Research Antibodies Market, By Research Area, 2018 to 20248.2.3. North America Research Antibodies Market, By Technology, 2018 to 20248.2.4. By Country8.2.4.1. United States8.2.4.2. Canada8.2.4.3. Mexico8.3. South America8.3.1. South America Research Antibodies Market, By Type, 2018 to 20248.3.2. South America Research Antibodies Market, By Research Area, 2018 to 20248.3.3. South America Research Antibodies Market, By Technology, 2018 to 20248.3.4. By Country8.3.4.1. Brazil8.3.4.2. Argentina8.3.4.3. Others8.4. Europe8.4.1. Europe Research Antibodies Market, By Type, 2018 to 20248.4.2. Europe Research Antibodies Market, By Research Area, 2018 to 20248.4.3. Europe Research Antibodies Market, By Technology, 2018 to 20248.4.4. By Country8.4.4.1. Germany8.4.4.2. France8.4.4.3. United Kingdom8.4.4.4. Italy8.4.4.5. Others8.5. Middle East and Africa8.5.1. Middle East and Africa Research Antibodies Market, By Type, 2018 to 20248.5.2. Middle East and Africa Research Antibodies Market, By Research Area, 2018 to 20248.5.3. Middle East and Africa Research Antibodies Market, By Technology, 2018 to 20248.5.4. By Country8.5.4.1. Saudi Arabia8.5.4.2. Israel8.5.4.3. Others8.6. Asia Pacific8.6.1. Asia Pacific Research Antibodies Market, By Type, 2018 to 20248.6.2. Asia Pacific Research Antibodies Market, By Research Area, 2018 to 20248.6.3. Asia Pacific Research Antibodies Market, By Technology, 2018 to 20248.6.4. By Country8.6.4.1. China8.6.4.2. Japan8.6.4.3. South Korea8.6.4.4. India8.6.4.5. Others

9. Competitive Environment and Analysis9.1. Major Players and Strategy Analysis9.2. Emerging Players and Market Lucrativeness9.3. Mergers, Acquisitions, Agreements, and Collaborations9.4. Vendor Competitiveness Matrix

10. Company Profiles10.1. ProSci Incorporated10.2. Thermo Fisher Scientific Inc10.3. General Electric10.4. Merck KGaA10.5. Roche Diagnostics10.6. Janssen Global Services, LLC10.7. Rockland Immunochemicals Inc.10.8. ACROBiosystems10.9. Bio-Rad Laboratories, Inc10.10. Agilent Technologies, Inc.

11. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/4pzxlp

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the original post here:
Outlook on the Worldwide Research Antibodies Industry to 2024 - Mergers, Acquisitions, Agreements and Collaborations - GlobeNewswire

Megatrends: 5 Ways To Think Long Term In The Downturn – Seeking Alpha

Transcript

Oscar Pulido: The world is already starting to shift because of the coronavirus and there's no doubt this will continue in the months and years to come. Healthcare companies and researchers around the world are mobilizing to create a vaccine, technology has shifted to emphasize solutions for working at home, and clean energy has become even more in focus as companies and individuals think about their impact on the environment.

Today on The Bid, we're talking about megatrends. The long-term societal shifts that we believe will persist through the pandemic. We'll talk to Jeff Spiegel, U.S. Head of Megatrends and International ETFs about the long-term investment themes that emerged from the 2008 financial crisis, which megatrends are resonating most in today's pandemic and how to think about investing for the long term. I'm your host, Oscar Pulido. We hope you enjoy.

Jeff, thank you so much for joining us today on The Bid.

Jeff Spiegel: Oscar, thanks so much for having me. It wasn't a long commute as we're coming in live from my apartment in New York City.

Oscar Pulido: Oh, for sure. I'm in my home studio as well and been getting used to it over the last couple of weeks. So, I can definitely relate to that. Let's talk about the megatrends. It's actually been a topic that has come up a couple of times on The Bid, certainly a topic of interest for our listeners. Now, these are, as I understand, long-term structural forces that are shaping the way we live and work. But perhaps you can give us a quick refresh on what are the exact megatrends that we're watching.

Jeff Spiegel: So, as you said, megatrends are long-term transformational forces that are really changing the way we live and work. And these are structural opportunities with long-term catalysts that really make them feel almost inevitable, and that's in contrast to more purely cyclical opportunities as captured through traditional sector strategies and the like. Today, a number of them are actually having really once-in-a-lifetime moments where those long-term forces are aligning with short-term cyclical drivers.

Simply put, the world will be different after COVID-19. One example of that is going to be the acceleration of key megatrend themes that were already coming and are now going to arrive even faster. So, really to your question, as part of a firm-wide effort across active investors, index investors, the BlackRock Investment Institute, key external innovators and thought leaders, we've identified five. The first is technology: areas like AI, cybersecurity, networking, data. They're not mutually exclusive though, so tech does play a role in all five. The second is demographics. Here, we're talking about aging populations. For the first time in less than 10 years, there will be more grandparents than grandchildren in the U.S., more over 65s than under 18s, and that will be true worldwide shortly thereafter.

Third is urbanization, which is about the move to cities. Over 75% of people live in the cities and developed markets in Latin America. In the EM markets in Asia and Africa, that number is less than half. We're seeing that drive a massive catch-up effect as these places urbanize, and at the same time, the U.S., Japan, Europe, other developed areas seek to revitalize their own infrastructure. Fourth is climate change. Here, we're talking about firms on the cutting edge of driving a clean green tomorrow through clean energy, electric vehicles and the like. And lastly emerging global wealth. One to two billion people will enter the middle class in the coming decade or so and 90% of those people live in emerging market countries in Southeast Asia.

Oscar Pulido: So, Jeff, as you mention these five megatrends, it sounds like investing in any one of these is really about investing in multiple sectors of the economy. In other words, it doesn't sound like just technology companies capture one of these trends or just healthcare. It feels like you would have sort of cross-sector type investments if you were trying to pursue these megatrends. Is that the right way to think about it?

Jeff Spiegel: Exactly. So, we think that megatrend strategies should be designed in a way that they're unconstrained, and what I mean by that is you've got to go global, you've got to get across sectors. So much technological innovation is getting adopted in non-technology areas. Think about the use of robotics in industrials, the use of artificial intelligence in communication services, the use of big data techniques in medicine. Traditional sector strategies tend not to really capture megatrends, which again, gets back to that point that they tend to be cyclical.

Oscar Pulido: So, if megatrends are long-term and structural and meant to persist over many decades, you mentioned your commute is quite short these days. We're all living in a very new and different reality these last few weeks and it's difficult to think about the long term when it feels like we're just thinking about day-to-day and what the news flow is going to look like. So, do we have examples from the past where we've had these crises or these downturns where we've actually seen a long-term structural trend emerge?

Jeff Spiegel: Yeah, so it's absolutely hard to think long term right now and investors around the world are looking at their portfolios and seeing declines at the same time as they have real fears from job security to health and safety, and that make this moment especially tough. But we know that market downturns are also opportunities, rebalancing the equities during these declines allows investors to recoup their losses and often then some when the market does eventually come back and it always has.

So, cyclical downturns are often pivotal moments for megatrends. They may suffer with the broad market in a sell-off when selling can appear kind of indiscriminate across asset classes and market segments. Sometimes they can sell-off even harder than the overall market, but they tend to outperform in the aftermath. So, e-commerce is a really neat example of that. Before the financial crisis of 2008, 2009, we all knew e-commerce was coming, more shopping was happening online, firms were starting to dominate retail sales. Nonetheless, at the lows of that downturn, e-commerce was down nearly 70%, even more than the S&P 500 at its lows during that same period, but not only did e-commerce recover harder and faster than the S&P, it out-performed over the next 10 years through to today by well over 20 times the returns of U.S. equities broadly1. That means the financial crisis was a huge opportunity to buy the e-commerce megatrend at significantly reduced valuations. We think it's not unlikely that a new set of megatrends, today's equivalent to e-commerce, have the same potential coming out of this downturn.

Oscar Pulido: Well, you're certainly right, e-commerce was a trend that persisted throughout 2008 and judging by the lobby of my building, it seems to be doing pretty well during the corona crisis as well.

Jeff Spiegel: Yeah, so I would say that the farthest I am traveling on most days is to go down and get those packages and that is one of the highlights of my day at the moment to be sure.

Oscar Pulido: You mentioned that we'll likely see some new megatrends that will persist through today's market volatility. So, give us a sense of what are some of the things that you're seeing that you think we'll be talking about in the months and years ahead.

Jeff Spiegel: The megatrends we're focusing on right now are actually being accelerated by the crisis itself, and therefore the long-term structural shifts we've been anticipating seem likely to come to pass even faster. And this is true in a few areas in particular, and I'll break it down by megatrend. Within our technological breakthrough megatrend, we're seeing a huge move to virtual work, that's driving networks and computing systems, big data, cybersecurity, and at the same time, AI is being deployed to understand the pandemic's course, track infections and accelerate the testing of treatments. In demographics and social change, we're seeing the two most game-changing areas of medical breakthrough, genomics and immunology, stand unsurprisingly on the forefront of understanding and treating the disease. And then as far as urbanization and climate change, these are places where we expect that subsequent rounds of government stimulus have the potential to drive outperformance as people are put back to work in these areas. So, we know the long-term structural theses behind these megatrends. In addition, we've got these catalysts coming out of this crisis where some of these key areas of innovation are really playing a role and offering some hope and helping.

Oscar Pulido: You mentioned a number of interesting themes. So, let's deep dive. Let's start with the genomics and immunology. There's obviously a race around the world to produce a vaccine in pretty short order. So, how are we seeing this play out and what implications does this have for after a vaccine is ultimately developed?

Jeff Spiegel: So, the vaccine is a key question for society and our safety. In a lot of ways, I think there's actually a lot more to unpack there for investors. We saw genomics and immunology as key areas of medical innovation before all this started. Now genomics is helping researchers understand the coronavirus' RNA. Breakthroughs in mRNA sequencing are allowing scientists to decode the disease at an incredibly rapid pace. That's not actually the vaccine development itself, but it's enabling quick drug development and experimental trials for vaccines. So, the major drug companies at the forefront of vaccine development are relying on a range of firms in the field of genomics to enable them. For investors, that's a reason to think about the theme versus betting on the individual company that makes it to the vaccine, it's also a lot less risky than trying to pick that single stock winner.

Likewise, immunology is helping to incubate treatments that work directly with our immune systems. One of the most promising potential areas here is stimulating the body's immune system by replicating and transferring antibodies from those who have already successfully beaten the virus. Not to mention, repurposing drugs in immunology that are used in places like rheumatoid arthritis, an autoimmune disease; not to create vaccines, but to treat those who are already infected. Again, a range of firms across the theme are set to benefit rather than the one firm with the end product that's ultimately adopted. The latter, that one firm is really hard to identify. It's no coincidence that these exciting areas of medicine are providing the solution to this challenge. The crisis is really only hastening the realization that will see more innovation and investment in these spaces that were the most promising in delivering personalized medicine via genomics and areas like cancer treatments through immunology and immunotherapy long before today's crisis and that will continue to play a role long after.

Oscar Pulido: Let me also ask you about the technology side of this. When you were mentioning some of the megatrends that we think will persist throughout this volatility, we're working from home, we're doing more video conference, audio conference these days just to stay connected at our respective jobs or with our families. Do you think that even after people begin returning to working in offices, will there be more remote work than there was prior to the crisis?

Jeff Spiegel: So, I think the short answer is yes, right? If we think about this, in a matter of weeks, virtually all corporate employees around the globe started working from home, non-essential medical visits became virtual, so did learning for hundreds of millions of students, maybe more than that. So, companies leading in remote software have therefore seen their products leveraged at record rates. 5G and networking connectivity are also therefore in focus. So are data center wreaths which have seen surging demand for their services which power the transition. Is it the short term, is it long term? The answer is both.

The fact that the internet of things is expected to double from 30 billion devices now to over 75 billion in coming years, that was true before this pandemic, but it's not any less true today. In fact, we see the cyclical tailwind pushing connectivity forward, meaning that the future is actually coming faster. So, companies have invested in work from home tech. They are learning what many tech companies have known and been adopting for years that virtual work is actually effective and therefore likely to proliferate after this massive unplanned beta test that was effectively sprung on the world.

Oscar Pulido: And I imagine this has implications for cybersecurity, right? If companies have more of their employees working from home, they have to be thinking about the security risk. So, obviously more people on the networks and more people on the internet. How are companies thinking about the risks to this?

Jeff Spiegel: So, before we moved into a work from home world or WFH as the kids are calling it. Though I'm not entirely sure why since that's actually more syllables rather than fewer. Before that, only 15% of U.S. risk executives felt their firms were well-prepared for cyber threats. So even as the number of cyber criminals on the FBI's most wanted list went from a handful to over 40 in just the last few years, there is still that feeling of unpreparedness. That's pretty scary at a time when we're that much more exposed through virtual work. It means firms are massively investing in the space. And so, if we're right that virtual working actually grows and is accelerated once we're able to return to our offices then that investment in cybersecurity only continues.

Oscar Pulido: Jeff, you've also alluded to AI a couple of times or what we call artificial intelligence. It was a topic of interest even before we got into this corona crisis, but it seems to also be playing a role in a variety of ways in which we're responding to this crisis.

Jeff Spiegel: Yeah. This is a great example of where the structural and cyclical are colliding and really pushing megatrends forward. Year after year, we've been applying artificial intelligence to solving new problems from chess to logistics, to voice-activated assistance, that's a long-term trend. And today, AI is being applied to a range of crisis areas: understanding and mapping the pandemic, keeping track of those under quarantine. Not to mention, many leading AI firms are actually lending their AI super computing power to drug companies enabling testing of treatments in days versus the months it would take using natural or more traditional computing power.

Oscar Pulido: And lastly, you mentioned clean energy, and you also touched on climate change being one of the five megatrends. We've definitely seen a growing interest in sustainability and BlackRock has certainly been very vocal about the belief that climate change represents investment risk in portfolios. But can you talk a little bit about the growing interest in sustainability and maybe more specifically renewable power. How do you see this continuing through the pandemic?

Jeff Spiegel: So, over the last few years, we've seen a surge around clean energy adoption and usage. In fact, governments have pledged two trillion dollars of renewable investments in the near term. In a push driven by governments themselves, businesses, consumers, all around the world looking to go more green. Another stat I really like, 80% of U.S. consumers aged 18 to 34 are actually willing to pay more for a low or zero emission vehicle. That's the long-term trend. Short term, the stimulus the government is focused on so far is getting cash into the pockets of those who need it and ensuring the financial system keeps functioning.

In the midterm, in subsequent rounds of stimulus, governments around the world are likely to put people back to work through infrastructure projects and a lot of those, we think, will be focused on clean energy. So, despite the precipitous decline of oil, clean energy has been doing well and we expect that to continue or even accelerate even further when we see those later rounds of stimulus putting people back to work in helping us build out a green economy.

Oscar Pulido: So, a recurring point that you've made is that these investment themes, these megatrends, are much more structural than they are cyclical. Meaning, that they're meant to last over many years as opposed to just a short time period. So, I guess with that, what's the most important thing for investors to know?

Jeff Spiegel: The most important thing for investors to know unquestionably is that staying invested and rebalancing the equities is critical in a downturn. As we discussed, it's also hardest in a downturn. Long-term structural shifts do present an opportunity to do that. So, I would encourage investors to look at areas with a wide range of names poised for that long-term outperformance and names that were poised for it even before this crisis. Just take as a bonus, if they're being accelerated forward, by helping us manage the pandemic at the same time. Think long term, that's always the key.

Oscar Pulido: Well, and it's sound advice, Jeff. Particularly these days when we're sort of thinking about the day-to-day and the pandemic. But when it comes to investing, thinking long-term has proven to be a recipe for success. So, thank you so much for joining us today. It was a pleasure having you on The Bid.

Jeff Spiegel: Pleasure to be here. Thanks, Oscar.

1 Source: Bloomberg, indices used: MSCI ACWI Internet and Catalog Retail Index and S&P 500 as of March 30, 2020. Index performance is for illustrative purposes only.

This post originally appeared on BlackRock.

Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.

See the original post here:
Megatrends: 5 Ways To Think Long Term In The Downturn - Seeking Alpha

Demand for Immunology Drug Skyrockets with the Surge in Covid-19 Cases, Supporting Global Revenue – Jewish Life News

In 2018, the market size of Immunology Drug Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Immunology Drug market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Immunology Drug market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Immunology Drug market to assist our clients arrive at beneficial business decisions.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/15259

This study presents the Immunology Drug Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Immunology Drug history breakdown data from 2014 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2018.

In global Immunology Drug market, the following companies are covered:

key players and products offered

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/15259

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Immunology Drug product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Immunology Drug , with price, sales, revenue and global market share of Immunology Drug in 2017 and 2018.

Chapter 3, the Immunology Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Immunology Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2018.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/15259

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2018.

Chapter 12, Immunology Drug market forecast, by regions, type and application, with sales and revenue, from 2018 to 2024.

Chapter 13, 14 and 15, to describe Immunology Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Read more from the original source:
Demand for Immunology Drug Skyrockets with the Surge in Covid-19 Cases, Supporting Global Revenue - Jewish Life News

Hangover cure: Key could be eating fruits, roots and leaves – study finds – Sky News

Everyone has their own way of curing hangovers, whether it is painkillers or a fry-up. But new research suggests plants could hold the key to keeping them at bay.

Analysis by scientists at the Institute of Molecular Physiology in Mainz, Germany, found that people who consume a combination of fruits, leaves and roots will be less likely to feel ill.

The headaches and nausea most commonly associated with a hangover had been thought to be caused by a lack of electrolytes in the body, a combination of minerals that help balance acid levels.

But the research showed that people who took on board extra plant extracts and minerals after drinking suffered fewer hangover symptoms than those who just consumed more minerals.

The study, published in the British Medical Journal Nutrition Prevention and Health, suggested a combination of fruits, leaves, and roots reduced head pain and sickness.

A total of 69 healthy 18 to 65-year-olds were given water with a supplement including ginger root, Barbados cherry, magnesium, potassium and other plants and minerals.

They were given the drink 45 minutes before, and immediately after they stopped drinking beer, white wine, or white wine spritzer.

A second group of 76 people were given the supplement minus the plant extracts, and a third group of 69 were given a test placebo.

When questioned afterwards, those who had taken the plant and mineral mix found average headache intensity was 34% less, nausea 42% less, while feelings of indifference fell by an average of 27% and restlessness by 41%.

No significant difference in any symptom was reported by those taking the supplement minus the plant extracts, suggesting that plant extracts were largely responsible for the observed changes, researchers said.

Follow this link:
Hangover cure: Key could be eating fruits, roots and leaves - study finds - Sky News

The Evolutionary Reasons Behind Why We Hiccup – The Swaddle

Hiccups the annoying, stubborn interrupters we all love to hate have spurred many urban legend-like stories, mostly aimed at making us feel better when they happen. Someones thinking of you, or missing you, is the most common feel-good myth we have devised to explain away the mysterious phenomenon. Familial remedies of how to cure them are also manufactured out of the same imaginations count to seven and hold your breath; pull on your tongue, swallow a teaspoon of sugar. Needless to say, none of these are supported by any conclusive scientific evidence.

Hiccups have baffled scientists for a long time they are ubiquitous but provide no physiological advantage whatsoever. And if hiccups are a vestigial (essentially useless) phenomenon, then why does the evolved modern-day human still have them? What science does know about hiccups, thankfully, provides an equally absurd evolutionary explanation worthy of challenging even the best of imaginations.

Scientists believe the brain signals that facilitate hiccups are left over from a previous evolutionary stage. Hiccups are a recurring phenomenon, examples of which can be found throughout history. Take the tadpole, for instance at a certain point in its development, it starts to transition to a full-grown frog, at which point it has both gills (to breathe water) and lungs (to breathe air). When the tadpole breathes water, it closes the glottis (the opening of the vocal cords) so that the water doesnt go into the lungs, and instead can be passed through the gills. Scientists believe the mechanism in the brain that facilitates this periodic closing of the glottis, called central pattern generator (CPG), is a vestigial remnant from when some aquatic life slowly transitioned to land hundreds of millions of years ago.

Related on The Swaddle:

Why Sneezing Is So Weird

Today, this CPG functions in a similar way in humans. Hiccups arise out of a complicated motor act, during which the diaphragm and accompanying chest and neck muscles contract suddenly. When the diaphragm is irritated for example, from heartburn, ulcers, too much food or alcohol, it can suddenly contract, pulling downwards and sucking in air. This sudden contraction causes the glottis to snap shut, preventing any air from passing to the lungs, which produces the hic sound. The subsequent burp occurs as a result of the roof of the mouth, and the back of the tongue, moving up, allowing for a huge gasp of trapped air to escape out again. This has led scientists to surmise a CPG must exist in human brains that sends this recurring, periodic signal to control movement of the glottis, much like how actions like coughing and breathing are controlled.

The CPG, however, has evolved to be conditional. Humans are not hiccuping all the time, which led scientists to explore what triggers the CPG. This, however, proved not to be an easy feat. Most research surrounding hiccups can only be conducted among people who have a pathological hiccuping problem, which scientists have traced to an infection in the diaphragm, brain lesions, or issues with any of the nerves phrenic, vagus that carry messages to and fro between the involved neural and muscular systems. In addition to gastric problems, research shows physical trauma (to the head, for example) and tumors can also cause hiccups all of which affect the operations involved in hiccups, from the stomach to the brain and central nervous system.

Another theory for why hiccups happen involve babies in utero. While they get their oxygen from their mothers placenta while in the womb, they have to immediately learn to breathe once theyre born. You have to have a breathing apparatus that is already trained, a professor of gastroenterology at Northwestern University, Dr. Peter Kahrilas, tells Live Science. Hiccups begin in-utero, Kahrilas says, as a training mechanism for babies to learn to breathe, but because the fetuses are surrounded by a sac of blood and fluid, their glottis learns to snap shut to protect their lungs. Newborns also continue to hiccup frequently in the early years of their lives, which neurology and physiology research fellow at the University of London, Lorenzo Fabrizi tells Live Science, is a way for developing brains to form body maps that help babies acquaint themselves with their breathing apparatus.

These, however, are merely logical theories. As neuroscientist Robert Provine tells Vox Essentially, we still dont know what hiccups do, and our cure for them hasnt improved since Plato.

Follow this link:
The Evolutionary Reasons Behind Why We Hiccup - The Swaddle

Trying eating fruits, roots and leaves to tackle a hangover, say scientists – shropshirestar.com

Plant extracts could hold the key to curing hangovers, research suggests

Headaches and nausea after drinking had been thought to be caused by a lack of electrolytes in the body, a combination of minerals that help balance acid levels.

But analysis by scientists at the Institute of Molecular Physiology in Mainz, Germany, showed that people who took on board extra plant extracts and minerals after drinking suffered fewer hangover symptoms than those who just consumed more minerals.

The study published in the British Medical Journal Nutrition Prevention and Health suggested that a combination of fruits, leaves, and roots reduced head pain and sickness.

A total of 69 healthy 18 65-year-olds were given water with a supplement including ginger root, Barbados cherry, magnesium, potassium and other plants and minerals.

They were given the drink 45 minutes before, and immediately after they stopped drinking beer, white wine, or white wine spritzer.

A second group of 76 people were given the supplement minus the plant extracts, and a third group of 69 were given a test placebo.

When questioned afterwards, those who had taken the plant and mineral mix found average headache intensity was 34% less, nausea 42% less, while feelings of indifference fell by an average of 27% and restlessness by 41%.

No significant difference in any symptom was reported by those taking the supplement minus the plant extracts, suggesting that plant extracts were largely responsible for the observed changes, say the researchers.

View post:
Trying eating fruits, roots and leaves to tackle a hangover, say scientists - shropshirestar.com

COVID-19: Potential impact on Automated Biochemistry Analyzers Market top key players, size, Analysis, growth, research, Types, Regions and Forecast…

The novel Coronavirus (COVID-19) has caused a slowdown in the global economy and disrupted the stock markets. Hence, companies in the Automated Biochemistry Analyzers market are tapping incremental opportunities via alternative business solutions to revive market growth post the lockdown period. Get a full analysis report on the impact of Coronavirus which has affected the Automated Biochemistry Analyzers market and learn how businesses are tackling the situation.

Assessment of the Global Automated Biochemistry Analyzers Market

According to the latest report on the Automated Biochemistry Analyzers market, the market is expected to reach a value of ~US$XX by 20XX and register a CAGR growth of ~XX% during the forecast period (20XX-20XX). The report provides a thorough understanding of the various factors that are expected to influence the current and future prospects of the Automated Biochemistry Analyzers market including the major trends, growth opportunities, restraints, and drivers.

The SWOT and Porters Five Forces Analysis by analysts of ResearchMoz.us offers a fair idea of the operations of some of the key players operating in the Automated Biochemistry Analyzers market. The current structure of the market and the estimated growth of the market over the forecast period is accurately represented in the report along with graphs, figures, and tables.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2522592&source=atm

Segregation of the Automated Biochemistry Analyzers Market:

The following manufacturers are covered:AbbottDanaherHitachiRocheSiemensThermo Fisher Scientific

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeStationary Biochemistry AnalyzersPortable Biochemistry Analyzers

Segment by ApplicationHospital and Diagnostic LaboratoriesHome Care, and AcademicResearch Institutes

The report includes a Y-o-Y growth assessment of each of these market segments and sub-segments. Further, the market share, size, revenue growth, and CAGR growth of each segment is accurately presented in the in-depth study of the Automated Biochemistry Analyzers market.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2522592&source=atm

Valuable Insights Enclosed in the Report

The presented study resolves the following doubts related to the Automated Biochemistry Analyzers market:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2522592&licType=S&source=atm

See original here:
COVID-19: Potential impact on Automated Biochemistry Analyzers Market top key players, size, Analysis, growth, research, Types, Regions and Forecast...

Assessing the Fallout From the Coronavirus Pandemic Automatic Veterinary Biochemistry Analyzer Market Movement-detailed Research Analysis 2019-2027 -…

Analysis of the Global Automatic Veterinary Biochemistry Analyzer Market

The report on the global Automatic Veterinary Biochemistry Analyzer market reveals that the market is expected to grow at a CAGR of ~XX% during the considered forecast period (2019-2029) and estimated to reach a value of ~US$XX by the end of 2029. The latest report is a valuable tool for stakeholders, established market players, emerging players, and other entities to devise effective strategies to combat the impact of COVID-19

Further, by leveraging the insights enclosed in the report, market players can devise concise, impactful, and highly effective growth strategies to solidify their position in the Automatic Veterinary Biochemistry Analyzer market.

Research on the Automatic Veterinary Biochemistry Analyzer Market Addresses the Following Queries

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2607174&source=atm

Competitive Landscape

The competitive landscape section offers valuable insights related to the business prospects of leading market players operating in the Automatic Veterinary Biochemistry Analyzer market. The market share, product portfolio, pricing strategy, and growth strategies adopted by each market player is included in the report. The major steps taken by key players to address the business challenges put forward by the novel COVID-19 pandemic is discussed in the report.

Regional Landscape

The regional landscape section provides a deep understanding of the regulatory framework, current market trends, opportunities, and challenges faced by market players in each regional market. The various regions covered in the report include:

End-User Assessment

The report bifurcates the Automatic Veterinary Biochemistry Analyzer market based on different end users. The supply-demand ratio and consumption volume of each end-user is accurately depicted in the report.

Market Segment AnalysisThe research report includes specific segments by Type and by Application. Each type provides information about the production during the forecast period of 2015 to 2026. Application segment also provides consumption during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.Segment by TypeBench-Top Veterinary Biochemistry AnalyzerPortable Veterinary Biochemistry Analyzer

Segment by ApplicationPet HospitalVeterinary StationOther

Global Automatic Veterinary Biochemistry Analyzer Market: Regional AnalysisThe report offers in-depth assessment of the growth and other aspects of the Automatic Veterinary Biochemistry Analyzer market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.Global Automatic Veterinary Biochemistry Analyzer Market: Competitive LandscapeThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.The major players in the market include Biochemical Systems International, BPC BioSed, Carolina Liquid Chemistries, Abaxis Europe, AMS Alliance, Randox Laboratories, Rayto Life and Analytical Sciences, Scil Animal Care, Crony Instruments, DiaSys Diagnostic Systems, Eurolyser Diagnostica, Gesan Production, Heska, Idexx Laboratories, LITEON IT Corporation, Shenzhen Icubio Biomedical Technology, URIT Medical Electronic, etc.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2607174&source=atm

Essential Findings of the Automatic Veterinary Biochemistry Analyzer Market Report:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2607174&licType=S&source=atm

Here is the original post:
Assessing the Fallout From the Coronavirus Pandemic Automatic Veterinary Biochemistry Analyzer Market Movement-detailed Research Analysis 2019-2027 -...

Paying the bills when youve been out of work – Marketplace

For many of the more than 30 million Americans who lost their jobs in the past six weeks, tomorrow is a stressful due date: rent day. We caught up with three people we spoke to last month, when they suddenly became out of work, to hear how their financial lives changed in April.

April Oliver

April Oliver of Boseman, Montana, recently graduated with her masters degree in biochemistry and landed her dream job. However, her lab closed down before she was set to start working.

Oliver filed for unemployment but was told she didnt qualify due to a clerical error. However, Oliver received her official job offer because the lab is reopening.

I have to wait another month until my first paycheck, Oliver said. But we feel confident well be able to make bills and credit card payments on time.

Seth Schulman

Seth Schulman, a musician in Chicago, teaches private lessons at a local school and performs on the weekends. He hasnt been able to teach his students since mid-March, when the school closed, and live performances have stopped too. Like Maria Barillas, he applied for unemployment insurance over a month ago. However, he hasnt been able to receive any benefits yet.

Ive got a nice enough landlord to let me pay around half of my rent, Schulman said. But it feels pretty pathetic having to write a really long email or call them and be like, Hey, things really suck. Can you spare me a bone?

Schulman recently heard from the school he works at that he can start virtual lessons with his students, which will help him make ends meet.

Maria Barillas

Maria Barillas works as a server and barista at a Brooklyn restaurant that closed in mid-March due to the coronavirus outbreak. She almost immediately started collecting unemployment insurance, along with the extra $600 that was added because of this crisis.

Its basically given me a full weekly wage, Barillas said. I feel confident that as long as I have unemployment, I can pay for stuff.

Related Stories

Whats going on with oil prices?

In April the price of U.S. crude oil fell into negative territory for the first time ever. Essentially, that means producers are paying buyers to take supplies off their hands. But its hard for consumers to benefit from any price drop when lockdowns are in place and there is nowhere to go.

Is takeout food safe during COVID-19?

The short answer is yes. You can read the long answer, and all the caveats, here.

Is it worth applying for a job right now?

It never hurts to look, but as unemployment reaches levels last seen during the Great Depression and most available jobs are in places that carry risks like the supermarket or warehouses, it isnt a bad idea to sit tight either, if you can.

You can find answers to more questions here.

As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.

Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.

Donate today in any amount to become a Marketplace Investor. Now more than ever, your commitment makes a difference.

Read the original post:
Paying the bills when youve been out of work - Marketplace